Lombard Odier Asset Management Switzerland SA reduced its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 74.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 60,179 shares of the medical device company’s stock after selling 174,112 shares during the quarter. DexCom comprises 1.1% of Lombard Odier Asset Management Switzerland SA’s portfolio, making the stock its 27th biggest holding. Lombard Odier Asset Management Switzerland SA’s holdings in DexCom were worth $7,734,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Avalon Trust Co bought a new stake in shares of DexCom in the first quarter valued at about $26,000. Atlas Capital Advisors LLC bought a new position in DexCom during the second quarter worth about $33,000. TFC Financial Management Inc. boosted its holdings in DexCom by 4,814.3% during the first quarter. TFC Financial Management Inc. now owns 344 shares of the medical device company’s stock valued at $40,000 after purchasing an additional 337 shares in the last quarter. Valley National Advisers Inc. lifted its position in shares of DexCom by 33.5% during the 2nd quarter. Valley National Advisers Inc. now owns 379 shares of the medical device company’s stock worth $49,000 after buying an additional 95 shares during the period. Finally, Center for Financial Planning Inc. acquired a new stake in DexCom in the 2nd quarter valued at $51,000. 93.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DXCM has been the topic of several research analyst reports. TheStreet cut shares of DexCom from a “b-” rating to a “c+” rating in a research note on Wednesday, September 6th. Robert W. Baird reduced their target price on shares of DexCom from $153.00 to $130.00 and set an “outperform” rating on the stock in a research report on Monday, August 21st. StockNews.com started coverage on shares of DexCom in a research report on Thursday, October 5th. They set a “hold” rating on the stock. Stifel Nicolaus cut their price objective on shares of DexCom from $155.00 to $145.00 and set a “buy” rating on the stock in a report on Tuesday, October 10th. Finally, Leerink Partnrs restated an “outperform” rating on shares of DexCom in a report on Monday, October 16th. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and an average price target of $130.93.

View Our Latest Analysis on DXCM

DexCom Stock Up 1.0 %

Shares of DXCM stock traded up $1.16 during trading hours on Friday, hitting $116.68. 757,444 shares of the company were exchanged, compared to its average volume of 3,373,295. The business has a 50 day moving average of $93.50 and a two-hundred day moving average of $109.40. The company has a current ratio of 2.80, a quick ratio of 2.50 and a debt-to-equity ratio of 1.07. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $139.55. The company has a market capitalization of $45.08 billion, a PE ratio of 126.95, a PEG ratio of 2.41 and a beta of 1.13.

DexCom (NASDAQ:DXCM – Get Free Report) last issued its quarterly earnings data on Thursday, October 26th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.16. DexCom had a net margin of 11.08% and a return on equity of 25.05%. The company had revenue of $975.00 million during the quarter, compared to the consensus estimate of $939.64 million. During the same quarter in the prior year, the firm earned $0.28 earnings per share. The firm’s revenue was up 26.7% compared to the same quarter last year. Analysts anticipate that DexCom, Inc. will post 1.43 earnings per share for the current fiscal year.

Insider Activity at DexCom

In related news, Director Steven Robert Pacelli sold 411 shares of the firm’s stock in a transaction on Friday, November 24th. The shares were sold at an average price of $110.80, for a total value of $45,538.80. Following the completion of the transaction, the director now owns 124,775 shares of the company’s stock, valued at $13,825,070. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, EVP Barry J. Regan sold 2,019 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $95.22, for a total transaction of $192,249.18. Following the transaction, the executive vice president now directly owns 64,250 shares in the company, valued at approximately $6,117,885. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven Robert Pacelli sold 411 shares of the business’s stock in a transaction that occurred on Friday, November 24th. The stock was sold at an average price of $110.80, for a total value of $45,538.80. Following the transaction, the director now directly owns 124,775 shares in the company, valued at approximately $13,825,070. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,028 shares of company stock valued at $783,000. Corporate insiders own 0.41% of the company’s stock.

DexCom Company Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Featured Stories

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider DexCom, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and DexCom wasn’t on the list.

While DexCom currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here